Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Obesity Treatments

Roche CT-388 WVE-007

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Phase 3 trials are set to begin this quarter following 48-week topline data showing large placebo-adjusted weight loss.